Japanese scientists have discovered a bacterium living in tree frog intestines that wiped out colorectal cancer tumors in mice with a single intravenous dose, outperforming standard chemotherapy and immunotherapy in laboratory tests.
The bacterium, Ewingella americana, achieved a 100% complete response rate, meaning tumors disappeared entirely in the mouse models treated. Researchers at the Japan Advanced Institute of Science and Technology isolated the strain from Japanese tree frogs after screening 45 bacterial candidates collected from amphibians and reptiles.
The findings, published in Gut Microbes, represent a shift in how scientists think about using bacteria for cancer treatment. Rather than simply altering the gut microbiome or transferring fecal material, the team cultivated individual bacterial strains in the lab and delivered them directly into the bloodstream to hunt down malignant cells.
What makes E. americana unique is its ability to concentrate almost exclusively inside tumors while leaving healthy organs untouched. The bacterium thrives in the oxygen-starved environment at the core of tumors, where it multiplies roughly 3,000 fold within 24 hours after a single injection.
The cancer-killing action works through two complementary mechanisms. First, the bacteria physically damage tumor cells by expanding in the low-oxygen regions where conventional treatments struggle to penetrate. Second, they trigger an immune assault by attracting T cells, B cells, and neutrophils into the tumor mass. These immune cells then unleash inflammatory molecules like TNF-alpha and interferon-gamma that amplify the body's natural cancer-fighting response.
Safety tests showed the treatment carries minimal risk. The bacteria were cleared from the bloodstream in roughly 1.2 hours and disappeared entirely within 24 hours. No bacterial colonization was detected in the liver, spleen, lungs, kidneys, or heart. The only side effect was mild, temporary inflammation that resolved within three days, with no chronic toxicity observed during a 60-day monitoring period.
The tumor specificity appears to result from multiple biological factors converging inside cancer tissue. Tumors produce low oxygen levels that encourage bacterial growth. Cancer cells generate the CD47 protein, which dampens local immune activity and gives bacteria a foothold. Leaky tumor blood vessels make it easier for circulating bacteria to penetrate malignant tissue. And tumors create metabolic conditions that provide nutrients bacteria need to thrive.
The researchers emphasize these results are confined to mouse models and represent early-stage proof of concept. The next phase will test whether the approach works against other solid tumors like breast cancer, pancreatic cancer, and melanoma. Scientists also plan to experiment with dose timing, direct injection into tumors, and combinations with existing chemotherapy or checkpoint inhibitor drugs.
The discovery highlights a broader potential: mining Earth's biodiversity for organisms with therapeutic properties. Amphibians and reptiles in particular have yielded compounds and microbes with biomedical value, and the ability to screen bacterial strains from these species could unlock treatments for cancers that resist conventional approaches.
Author Jessica Williams: "This is exactly the kind of unconventional thinking that could break open treatment resistance, but mouse studies notoriously fail to translate in humans, so the hype needs to stay measured until clinical trials prove otherwise."
Comments